SLAMF1 and Cowden disease: In line with the systemic nature of CD inflammation, the finding that circulating SLAMF1 positive ILC2s are increased in patients with inactive disease suggests that the expansion of SLAMF1 positive ILC2s may be considered as an interesting therapeutic strategy [64].